Evaluation of the Potential Pharmaological Effect of Cactacea Nopalea cochenillifera
Nopalea cochenillifera; Cactacea; Gastroprotection; Anti-inflammatory; Flavonoids; Herbal Medicine.
Nopalea cochenillifera, from the Cactaceae family, is popularly known as "sweet" or "small" palm and is widely cultivated in the northeastern region of Brazil, therefore, a source of abundant raw material for the development of herbal medicine. The aim of this study was to evaluate the gastroprotective, anti-inflammatory and healing effect, in addition to the phytochemical profile of an extract of N. cochenillifera. For analysis of the phytochemical profile, Thin Layer Chromatography (CCD) and High Efficiency Liquid Chromatography Coupled to the Mass Spectrometer (CLAE-EM) were performed and the content of total phenols and flavonoids was evaluated by UV spectrophotometer. For the evaluation of gastroprotective activity, the experimental model of acute ulcer induced by ethanol and indomethacin was used in Wistar rats. For the pre-treatment, N. cochenillifera extracts were used in doses of 50, 100, 200 and 300 mg / kg and ranitidine (50 mg / kg) as a standard drug, orally. The antiinflammatory activity was assessed using the experimental model of carrageenaninduced paw edema in Swiss mice. For the treatment, doses of 200, 400 and 600 mg / kg of N. cochenillifera were used and as a standard drug dexamethasone (1 mg / kg), orally. Through CCD it was observed bands with yellow color after revealed with Natural Reagent A and vanillin, which suggests the presence of flavonoids. The content of phenols and total flavonoids in the hydroethanolic extract of N. cochenillifera was 34.9% and 33.03, respectively. The CLAE-EM was identified 06 compounds, the predominant compound was hexoside caffeic acid. In the assessment of gastroprotective activity, pretreatment with N. cochenillifera extract at a dose of 100 mg / kg (p <0.001) significantly reduced gastric lesions when compared to the positive group. Regarding the percentage of inhibition of gastric lesions (I%), it was observed that pretreatment with ranitidine (50 mg / kg) was able to inhibit 70.61% of the lesions, while doses of 50, 100, 200 and 300 mg / kg of N. cochenillifera showed a percentage of inhibition of 25.4%, 58.53%, 24.5% and 35.89%, respectively, with the best result being observed with the dose of 100 mg / kg . In addition to the reduction of gastric lesions, it was also observed that N. cochenillifera extracts and ranitidine were able to reduce the activity of the myeloperoxidase (MPO) enzyme. In the indomethacin-induced gastric lesion model, pretreatment with N. cochenillifera extract showed significant results at doses of 100 mg / kg (p <0.05) and 200 mg / kg (p <0.01) when compared with the positive control. Ranitidine in the experiment showed 82.31% of ulcer inhibition, however, the doses of 50, 100 and 200 mg / kg showed inhibited 35.79%, 48.11%, and 49.90% of the lesion, respectively, when compared to positive control. In the histological study at doses of 50, 200 and 300 mg / kg, mild to severe lesions of the mucosa with leukocyte infiltration of the submucosal layer were observed, however, the dose of 100 mg / kg showed an organized mucosa with little damage. In the paw edema model, it was observed that the dose of 600 mg / kg showed a better result with edema inhibition in 58.00 ± 6.02 (p <0.01) when compared with the negative control group. A reduction in the levels of the MPO enzyme was also observed. Therefore, 06 compounds were characterized by HPLC-MS, it can be suggested that through these preliminary studies that N. cochenillifera extract shows potential effect gastroprotective and anti-inflammatory in in vivo models and it can be relate to the presence of phenolic compounds.